Sopharma AD produces, distributes, and exports pharmaceutical products in Europe, Bulgaria, and internationally. The company operates through Production of Pharmaceutical Products; Distribution of Pharmaceutical Products (Goods); and Others. It offers Carsil to treat liver disease; Tempalgin and Analgin, a painkiller; Tabex, drug used for smoking secession; Tribestan, drug used for stimulation of the male reproductive system; Broncholytin, which is used to suppress cough; Nivalin, used for diseases of the peripheral nervous system; Methylprednisolon, for severe allergies and life-threatening conditions; Vitamin C; Valeriana, used to reduce the stress; and medical devices, such as gauzes, compresses, and dressing. The company also provides food supplements; medicinal cosmetics, including plasters, bandages, and sanitary-hygiene products focused; and prescription medicines, on the counter products, and veterinary products. In addition, the company distributes pharmaceuticals, medical supplies, sanitary materials, vitamins, food supplements, and cosmetics; and provides contract manufacturing services; packaging services; and product development services. Further, it is involved in trading of food supplements; secondary packaging services for pharmaceutical products and real estate leases; trades, transports, and packages radioactive materials and nuclear equipment for medicinal use, household electronics, and electrical equipment; purchases, grows, produces, and trades in herbs and medicinal plant; and provision of public opinion research services. Additionally, the company engages in the offline and online retail trade of medicinal products and medical equipment; production of non-medicinal, and other products; and franchising, know-how, and rental of properties, as well as in trading, consulting, and other activities. Sopharma AD was founded in 1933 and is headquartered in Sofia, Bulgaria.
Metrics to compare | BGSFA | Sector Sector - Average of metrics from a broad group of related Consumer Non-Cyclicals sector companies | Relationship RelationshipBGSFAPeersSector | |
---|---|---|---|---|
P/E Ratio | 12.7x | 20.5x | −0.6x | |
PEG Ratio | −0.39 | 0.10 | 0.00 | |
Price/Book | 1.2x | 5.4x | 2.6x | |
Price / LTM Sales | 0.5x | 3.5x | 3.2x | |
Upside (Analyst Target) | 20.2% | 4.0% | 48.4% | |
Fair Value Upside | Unlock | 8.4% | 6.8% | Unlock |